The Flowr Corporation (TSX.V: FLWR; OTC: FLWPF) (“Flowr” or the
“Company”) today announced its FlowrRx products are now available
for purchase through Shoppers Drug Mart’s online medical cannabis
site, shoppersdrugmart.ca/cannabis.
On January 9, 2019, the two companies confirmed a sales
agreement. This new relationship represents a major milestone in
the de-stigmatization of medical cannabis’ place in mainstream
medicine, and in simplifying cannabis delivery in Canada. Medical
Cannabis by Shoppers Drug Mart is currently available only to
patients in Ontario.
“We’re pleased to provide patients with the high quality and
consistent products they seek, now with access to the world class
patient care team that Shoppers Drug Mart has assembled,” said
Vinay Tolia, Flowr’s Co-CEO. “Flowr’s premium medical cannabis
is grown in what we believe is the industry’s most advanced GMP
designed cultivation facility. This relationship is testament to
our commitment to ultra-high-quality cannabis cultivation and
further solidifies Flowr’s role in Canada’s medical cannabis
landscape.”
Flowr announced in January that it had entered into an agreement
to supply medical cannabis to Shoppers Drug Mart, creating the
opportunity to significantly increase sales of Flowr’s medical
cannabis products in Canada. Under the agreement, Shoppers Drug
Mart will be the exclusive direct-to-patient online provider of
FlowrRx products. Previously FlowrRx products were available online
to patients registered via Flowr’s website.
To make an order, patients must submit a completed medical
document from a health care practitioner to Shoppers Drug Mart
directly to begin the process. Advisers will then contact the
referring HCP to verify, then approve the patient who will be able
to order immediately.
About The Flowr Corporation
Flowr, through its subsidiaries, holds a cannabis production and
sales license granted by Health Canada. With a head office in
Toronto and a production facility in Kelowna, BC, Flowr builds and
operates large-scale, GMP-designed cultivation facilities utilizing
its own growing systems. Flowr's investment in research and
development along with its sense of craftsmanship and a spirit of
innovation is expected to enable it to provide premium-quality
cannabis that appeals to the adult-use recreational market and
addresses specific patient needs in the medicinal market.
For more information, visit www.flowr.ca. Follow Flowr on
Twitter: @FlowrCanada; Facebook: Flowr Canada; Instagram:
@flowrcanada; and LinkedIn: The Flowr Corporation.
On behalf of the Flowr Corporation:
Vinay Tolia
Co-CEO and Director
Forward-Looking Information
This press release includes forward-looking information within
the meaning of Canadian securities laws regarding Flowr and its
business, which may include, but are not limited to: the Shoppers
partnership being a major milestone in the de-stigmatization of
medical cannabis’ place in mainstream medicine and in simplifying
cannabis delivery in Canada, Shoppers planning to expand online
nationwide and in-store in the near future, Shoppers providing
access to a world class patient care team, Flowr’s products being
grown in what it believes is the industry’s most advanced GMP
designed cultivation facility, the Shoppers partnership solidifying
Flowr’s role in Canada’s medical cannabis landscape, the Shoppers
partnership creating the opportunity to significantly increase
sales of Flowr’s medical cannabis products in Canada, Flowr’s
facilities being designed in a way that should enable it to provide
patients with both high quality products and consistent benefits,
Flowr’s investment in research and development along with its sense
of craftsmanship and a spirit of innovation enabling it to provide
premium-quality cannabis that appeals to the adult-use recreational
market and addresses specific patient needs in the medicinal market
and other factors. Often, but not always, forward-looking
information can be identified by the use of words such as “plans”,
“is expected”, “expects”, “scheduled”, “intends”, “contemplates”,
“anticipates”, “believes”, “proposes” or variations (including
negative and grammatical variations) of such words and phrases, or
state that certain actions, events or results “may”, “could”,
“would”, “might” or “will” be taken, occur or be achieved. Such
statements are based on the current expectations of Flowr’s
management and are based on assumptions and subject to risks and
uncertainties. Although Flowr’s management believes that the
assumptions underlying these statements are reasonable, they may
prove to be incorrect. The forward-looking events and circumstances
discussed in this press release may not occur by certain specified
dates or at all and could differ materially as a result of known
and unknown risk factors and uncertainties affecting Flowr,
including risks relating to the inability to continue to supply
patients online, the inability of the Flowr products providing
Shoppers’ clients with a premium option, Flowr’s cultivation team
failing to achieve the standards or level of products described
herein, including with respect to quality and consistency of
product offerings, the supply agreement with Shoppers not providing
Flowr with the benefits described herein, including, without
limitation, not increasing sales of Flowr’s medical products, the
inability of Flowr to capture any portion of the expected Canadian
medical cannabis market, the inability of Flowr to maintain its
facilities at the standards described herein and using strict
processes to enable it to provide patients with high quality and
consistent products, which could significantly impact sales of
Flowr’s products, the Shoppers partnership not de-stigmatization
medical cannabis’ place in mainstream medicine and in simplifying
cannabis delivery in Canada, Shoppers not expanding its product
offerings online nationwide and in-store in the near future or at
all, which could have a material adverse effect on sales of Flowr’s
products, Shoppers not providing patients with access to a world
class patient care team, Flowr’s facility failing to be the
industry’s most advanced GMP designed cultivation facility, which
could significantly impact the quality and safety of Flowr’s
products, the Shoppers partnership not solidifying Flowr’s role in
Canada’s medical cannabis landscape, Flowr not being able to
provide premium-quality cannabis that appeals to the adult-use
recreational market and addresses specific patient needs in the
medicinal market, Flowr’s inability to excel at cultivating premium
cannabis, Flowr’s inability to construct its facilities, or in the
time anticipated, Flowr requiring additional financing from time to
time in order to continue its operations and such financing may not
be available when needed or on terms and conditions acceptable to
the Company, new laws or regulations adversely affecting the
Company’s business and results of operations, results of operation
activities and development of projects, project cost overruns or
unanticipated costs and expenses, the inability
of Flowr’s products to be high quality, the inability of
Flowr to produce and distribute premium, high quality products, the
inability to supply products or any delay in such supply, which
could result in significant penalties or costs being imposed on
Flowr, Flowr’s securities, the inability to generate cash flows,
revenues and/or stable margins, the inability to grow organically,
risks associated with the geographic markets in which Flowr
operates and/or distributes its products, risks associated with
fluctuations in exchange rates (including, without limitation,
fluctuations in currencies), risks associated with the use of
Flowr’s products, the cannabis industry and the regulation thereof,
the failure to comply with applicable laws, risks relating to
partnership arrangements, possible failure to realize the
anticipated benefits of partnership arrangements, including those
described herein, product launches (including, without limitation,
unsuccessful product launches), the inability to launch products,
the failure to obtain regulatory approvals, economic factors,
market conditions, risks associated with the acquisition and/or
launch of products, the equity and debt markets generally, risks
associated with growth and competition (including, without
limitation, with respect to Flowr’s products), general economic and
stock market conditions, risks and uncertainties detailed from time
to time in Flowr’s filings with the Canadian Securities
Administrators and many other factors beyond the control of
Flowr. Although Flowr has attempted to identify important
factors that could cause actual actions, events or results to
differ materially from those described in forward-looking
information, there may be other factors that cause actions, events
or results to differ from those anticipated, estimated or intended.
No forward-looking information can be guaranteed. Except as
required by applicable securities laws, forward-looking information
speaks only as of the date on which it is made and Flowr undertakes
no obligation to publicly update or revise any forward-looking
information, whether as a result of new information, future events,
or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this press release.
U.S. MEDIA: Tim Streeb
+1-646-677-1800
Tim.Streeb@icrinc.com
CANADIAN MEDIA: Rebecca Brown
+1-647-456-5599
rebecca@crowns.agency
FOR INVESTORS ONLY: Bram Judd
The Flowr Corporation
+1-647-483-7065 ext. 1520
bram@flowr.ca
FOR INVESTORS ONLY: Raphael Gross
+1-203-682-8253
Raphael.Gross@icrinc.com
The Flowr (TSXV:FLWR)
Historical Stock Chart
From Apr 2024 to May 2024
The Flowr (TSXV:FLWR)
Historical Stock Chart
From May 2023 to May 2024